Payment overview · 2025
General Payments
$634.31
24 reported records · 12 companies
Healthcare provider profile · identity verified
Deborah Schulte Long, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DULUTH, GA · NPI 1598712713
Verified facts
What the public records show
CMS Open Payments records show Deborah Schulte Long, CFNP received $634.31 in general payments during 2025 across 24 reported records.
Amgen Inc. accounted for 56.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $360.30 | 56.8% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.97 | 8.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $46.71 | 7.4% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $23.13 | 3.6% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.08 | 3.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $21.35 | 3.4% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.71 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.51 | 3.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.89 | 3.0% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $17.32 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.99 | 2.5% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $15.35 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $634.31 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $292.62 | 6 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $46.71 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.48 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.03 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 231 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 59 |
| Lisinopril | Lisinopril | 175 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 54 |
| Metformin Hcl | Metformin Hcl | 130 | 45 |
| Losartan Potassium | Losartan Potassium | 111 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 36 |
| Famotidine | Famotidine | 105 | 35 |
| Omeprazole | Omeprazole | 97 | 34 |
| Simvastatin | Simvastatin | 95 | 26 |
| Carvedilol | Carvedilol | 88 | 23 |
| Gabapentin | Gabapentin | 82 | 33 |
| Trazodone Hcl | Trazodone Hcl | 79 | 24 |
| Montelukast Sodium | Montelukast Sodium | 65 | 18 |
| Allopurinol | Allopurinol | 63 | 18 |
| Synthroid | Levothyroxine Sodium | 55 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 16 |
| Buspirone Hcl | Buspirone Hcl | 49 | 20 |
| Atenolol | Atenolol | 48 | 16 |
| Ozempic | Semaglutide | 48 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Sertraline Hcl | Sertraline Hcl | 47 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Glipizide Er | Glipizide | 41 | 14 |
| Furosemide | Furosemide | 40 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 17 |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Meloxicam | Meloxicam | 34 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 21 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 11 |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $634.31 · 24 records | Amgen Inc. | Bimzelx, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, Hillrom - Vest System Model 105 Home Care, ORENCIA, OTEZLA, Ozempic, PEMGARDA, PROLIA, PURIFIED CORTROPHIN GEL, QUTENZA, REPATHA, Rybelsus, TEPEZZA, TREMFYA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error